



Multiple Myeloma: Recent Advances in Diagnosis, Analysis and Therapeutic Management

Guest Editor:

Dr. Juan Manuel Rosa-Rosa

Instituto de Investigación
Sanitaria Hospital 12 de Octubre,
Madrid, Spain

Deadline for manuscript
submissions:

20 February 2025

Message from the Guest Editor

Dear Colleagues,

Many studies have demonstrated multiple myeloma (MM) to be a complex and heterogeneous disease, with an expansion of genetic events that impact the prognosis of patients. Currently, next-generation sequencing allows for the understanding and classification of the genomic landscape of MM, in which the presence of “high-risk” features keeps predicting poorer outcomes, regardless of the effectiveness of novel treatments. Thus, multiple myeloma is still considered incurable, although recent clinical trials have shown promising results in regard to the stabilization of the disease, furthering the five-year threshold. However, there still remain many features requiring consideration, with the rise in improved disease monitorization through the use of the minimal residual disease analysis and its association with relapse probability.

Inviting contributions: This Special Issue welcomes research articles and review papers focused on a wide scope of multiple myeloma, from basic pathology to preclinical and clinical studies.

Dr. Juan Manuel Rosa-Rosa
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)